Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2026)

Amylyx Pharmaceuticals' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$36.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 7.41% year-over-year to -$36.9 million; the TTM figure through Mar 2026 stood at -$120.5 million (up 41.8% YoY), while the FY2025 annual figure was -$123.5 million, up 26.41% from the prior year.
• Free Cash Flow was -$36.9 million for Q1 2026 at Amylyx Pharmaceuticals, down from -$28.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $13.2 million in Q4 2023 to a low of -$66.7 million in Q2 2024.
• Historically, Free Cash Flow has averaged -$29.4 million across 5 years, with a median of -$36.9 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow soared 126.22% in 2023, then slumped 7064.57% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$50.3 million in 2022, then jumped by 126.22% to $13.2 million in 2023, then sank by 547.35% to -$59.0 million in 2024, then jumped by 52.58% to -$28.0 million in 2025, then tumbled by 31.77% to -$36.9 million in 2026.
• The last three Free Cash Flow figures came in at -$36.9 million (Q1 2026), -$28.0 million (Q4 2025), and -$30.4 million (Q3 2025), per Business Quant data.